Abstract
Chemokine (C-X-C motif) receptor 4 (CXCR4) has been found to closely correlate with the incidence, development, treatment and prognosis of breast cancer. The aim of the present study was to investigate the effects of CXCR4 on bone metastasis in breast cancer and to explore the mechanisms of this process. CXCR4 small interfering RNA was transfected into the breast cancer cell line, MDA-MB-231BA-rfp, and the cell proliferation and invasion abilities of the cells were measured using cell counting kit-8 cell proliferation and Transwell assays. A mouse model of breast cancer with bone metastasis was prepared and the bone metastasis was confirmed using micro-positron emission tomography. The associated proteins were detected by western blot analysis and the results showed that CXCR4 RNAi inhibited the cell proliferation and invasion ability of the MDA-MB-231BA-rfp cells. In addition, CXCR4 RNAi inhibited the duration and extent of bone metastasis in the MDA-MB-231BA-rfp cells in the mouse model, while the inhibition of CXCR4 RNAi blocked the phosphatidylinositide 3-kinase (PI3K)/protein kinase B (AKT)/matrix metalloproteinase (MMP)-9 pathway. In conclusion, the present study demonstrated that CXCR4 RNAi inhibits bone metastasis and the cell proliferation and invasion abilities of breast cancer cells. Furthermore, the CXCR4/PI3K/AKT/MMP-9 pathway may be important in the bone metastasis of breast cancer.
Introduction
Breast cancer remains a leading cause of cancer-related mortality in women, largely due to its propensity to metastasize. Bone is one of the most frequent sites for these secondary tumors, leading to pain, fractures, and a significantly worsened prognosis. Scientists have long known that the chemokine receptor CXCR4 is overexpressed in many cancers and plays a role in "homing" cancer cells to specific organs. This study seeks to confirm if silencing CXCR4 can stop bone metastasis in a living model and to identify the specific signaling cascade responsible for this effect.
Methodology
The researchers employed a multi-stage experimental approach combining molecular biology and in vivo imaging. They used small interfering RNAs (siRNAs) to silence the CXCR4 gene in the MDA-MB-231BA-rfp cell line. Cell behavior was assessed using CCK-8 assays for proliferation and Transwell assays for invasion. Systemic spread was simulated in nude mice, with metastasis tracked in real-time using micro-positron emission tomography (micro-PET). Finally, Western blotting was used to quantify the expression of downstream signaling proteins: PI3K, AKT, and MMP-9.
Results and Discussion
Optimization of CXCR4 Silencing
The study tested multiple siRNA sequences, finding that sequence S2 achieved a 92% interference efficiency. Western blot analysis confirmed a clear dose-dependent inhibition: higher concentrations of CXCR4 siRNA led to lower rates of cell proliferation and invasion.
Impact on Metastasis and Signaling
In the animal model, bone invasion was visible via micro-PET within 4 weeks in the control group, whereas the CXCR4-silenced group showed a delay until the 6th week. The metabolic activity of tumors (SUVmax) was significantly lower in the interference group (2.13 ± 0.21) compared to the control (9.38 ± 0.54).
Mechanistically, the researchers identified the PI3K/AKT/MMP-9 signaling pathway as the critical driver. CXCR4 knockdown directly led to a massive drop in MMP-9 levels—an enzyme that allows cancer cells to clear a path through tissue—mediated by the PI3K/AKT survival hub.
Conclusion
The study demonstrates that CXCR4 RNAi inhibits bone metastasis and the cell proliferation and invasion abilities of breast cancer cells. The CXCR4/PI3K/AKT/MMP-9 pathway appears to be a primary mechanism for this progression. While clinical delivery of siRNA remains a challenge, these findings highlight this signaling axis as a prime target for future drug development to prevent metastatic spread.
Summary updated